Gen İlaç signs exclusive distribution deal for two products
The agreement gives GEN İlaç exclusive rights to register, sell, market and distribute Niktimvo in Turkey and Opzelura in Turkey and Azerbaijan.
Key takeaways
- GEN İlaç signed the agreement with Incyte Biosciences International on October 9, 2026.
- The five-year terms begin from each product’s first commercial sale in its market.
GEN İlaç signed a supply and distribution agreement with Incyte Biosciences International Sàrl on October 9, giving it exclusive rights for two products in Turkey and Azerbaijan, according to the company’s KAP filing.
The rights cover Niktimvo (axatilimab) in Turkey and Opzelura (ruxolitinib) in Turkey and Azerbaijan. They include licensing, sales, marketing and distribution.
Each product’s agreement term is five years from its first commercial sale in the relevant market. The filing does not state when sales will begin or estimate revenue.
The company said it expects the agreement to support its commercial activities and growth targets. For shareholders, it establishes exclusive commercial rights in the named markets, but the filing does not quantify their financial impact.
This article was produced with the help of AI technology. Source: Yahoo Finance
